Abnormal myosin post‐translational modifications and ATP turnover time associated with human congenital myopathy‐related RYR1 mutations

AIM Conditions related to mutations in the gene encoding the skeletal muscle ryanodine receptor 1 (RYR1) are genetic muscle disorders and include congenital myopathies with permanent weakness, as well as episodic phenotypes such as rhabdomyolysis/myalgia. Although RYR1 dysfunction is the primary mechanism in RYR1-related disorders, other downstream pathogenic events are less well understood and may include a secondary remodeling of major contractile proteins. Hence, in the present study, we aimed to investigate whether congenital myopathy-related RYR1 mutations alter the regulation of the most abundant contractile protein, myosin. METHODS We used skeletal muscle tissues from five patients with RYR1-related congenital myopathy and compared those with five controls and five patients with RYR1-related rhabdomyolysis/myalgia. We then defined post-translational modifications on myosin heavy chains (MyHCs) using LC/MS. In parallel, we determined myosin relaxed states using Mant-ATP chase experiments and performed molecular dynamics (MD) simulations. RESULTS LC/MS revealed two additional phosphorylations (Thr1309-P and Ser1362-P) and one acetylation (Lys1410-Ac) on the β/slow MyHC of patients with congenital myopathy. This method also identified six acetylations that were lacking on MyHC type IIa of these patients (Lys35-Ac, Lys663-Ac, Lys763-Ac, Lys1171-Ac, Lys1360-Ac, and Lys1733-Ac). MD simulations suggest that modifying myosin Ser1362 impacts the protein structure and dynamics. Finally, Mant-ATP chase experiments showed a faster ATP turnover time of myosin heads in the disordered-relaxed conformation. CONCLUSIONS Altogether, our results suggest that RYR1 mutations have secondary negative consequences on myosin structure and function, likely contributing to the congenital myopathic phenotype.

[1]  A. Beggs,et al.  Myosin post-translational modifications and function in the presence of myopathy-linked truncating MYH2 mutations. , 2023, American journal of physiology. Cell physiology.

[2]  A. Fornili,et al.  Comparative study of binding pocket structure and dynamics in cardiac and skeletal myosin , 2022, Biophysical journal.

[3]  J. Ochala,et al.  Myosin as a novel key modulator of striated muscle metabolism. , 2022, Physiology.

[4]  M. Regnier,et al.  Post-translational modification patterns on β-myosin heavy chain are altered in ischemic and nonischemic human hearts , 2022, eLife.

[5]  J. Ochala,et al.  Myofibre Hyper-Contractility in Horses Expressing the Myosin Heavy Chain Myopathy Mutation, MYH1E321G , 2021, Cells.

[6]  A. Brazma,et al.  The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences , 2021, Nucleic Acids Res..

[7]  A. Bjorksten,et al.  Pre-operative exercise and pyrexia as modifying factors in malignant hyperthermia (MH) , 2021, Neuromuscular Disorders.

[8]  N. Romero,et al.  rAAV-related therapy fully rescues myonuclear and myofilament function in X-linked myotubular myopathy , 2020, Acta neuropathologica communications.

[9]  Douglas E. V. Pires,et al.  DynaMut2: Assessing changes in stability and flexibility upon single and multiple point missense mutations , 2020, Protein science : a publication of the Protein Society.

[10]  P. Allen,et al.  Bioenergetic defects in muscle fibers of RYR1 mutant knock-in mice associated with malignant hyperthermia , 2020, The Journal of Biological Chemistry.

[11]  F. Muntoni,et al.  Therapeutic Aspects in Congenital Myopathies. , 2019, Seminars in pediatric neurology.

[12]  E. Hardeman,et al.  Impairments in contractility and cytoskeletal organisation cause nuclear defects in nemaline myopathy , 2019, bioRxiv.

[13]  J. Rendu,et al.  Phenotype and genotype of muscle ryanodine receptor rhabdomyolysis‐myalgia syndrome , 2018, Acta neurologica Scandinavica.

[14]  J. Spudich,et al.  Hypertrophic cardiomyopathy and the myosin mesa: viewing an old disease in a new light , 2017, Biophysical Reviews.

[15]  J. Seidman,et al.  Effects of myosin variants on interacting-heads motif explain distinct hypertrophic and dilated cardiomyopathy phenotypes , 2017, eLife.

[16]  M. Kawai,et al.  Myosin Rod Hypophosphorylation and CB Kinetics in Papillary Muscles from a TnC-A8V KI Mouse Model. , 2017, Biophysical journal.

[17]  K. Meilleur,et al.  Review of RyR1 pathway and associated pathomechanisms , 2016, Acta neuropathologica communications.

[18]  Francesco Muntoni,et al.  An RYR1 mutation associated with malignant hyperthermia is also associated with bleeding abnormalities , 2016, Science Signaling.

[19]  J. Thompson,et al.  S-Nitrosylation of Sarcomeric Proteins Depresses Myofilament Ca2+)Sensitivity in Intact Cardiomyocytes. , 2015, Antioxidants & redox signaling.

[20]  L. Leinwand,et al.  Skip residues modulate the structural properties of the myosin rod and guide thick filament assembly , 2015, Proceedings of the National Academy of Sciences.

[21]  B. Engelen,et al.  RYR1‐related myopathies: a wide spectrum of phenotypes throughout life , 2015, European journal of neurology.

[22]  R. Cooke,et al.  The role of super-relaxed myosin in skeletal and cardiac muscle , 2015, Biophysical Reviews.

[23]  J. Bergquist,et al.  Aberrant post-translational modifications compromise human myosin motor function in old age , 2015, Aging cell.

[24]  M. Roberts,et al.  Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis , 2013, Neuromuscular Disorders.

[25]  A. Oldfors,et al.  Myosinopathies: pathology and mechanisms , 2012, Acta Neuropathologica.

[26]  K. Bushby,et al.  Clinical and genetic findings in a large cohort of patients with ryanodine receptor 1 gene‐associated myopathies , 2012, Human mutation.

[27]  I. Azorín,et al.  Spanish MYH7 founder mutation of Italian ancestry causing a large cluster of Laing myopathy patients , 2012, Clinical Genetics.

[28]  Nicole M. Johnson,et al.  Genetic testing for dilated cardiomyopathy in clinical practice. , 2012, Journal of cardiac failure.

[29]  R. Dror,et al.  Systematic Validation of Protein Force Fields against Experimental Data , 2012, PloS one.

[30]  P. Jouk,et al.  Clinical and mutational spectrum in a cohort of 105 unrelated patients with dilated cardiomyopathy. , 2011, European journal of medical genetics.

[31]  Steffen Scheer,et al.  Novel correlations between the genotype and the phenotype of hypertrophic and dilated cardiomyopathy: results from the German Competence Network Heart Failure , 2011, European journal of heart failure.

[32]  J. Dowling,et al.  Prevalence of congenital myopathies in a representative pediatric united states population , 2011, Annals of neurology.

[33]  R. Cooke,et al.  A new state of cardiac myosin with very slow ATP turnover: a potential cardioprotective mechanism in the heart. , 2011, Biophysical journal.

[34]  J. Seidman,et al.  A novel custom resequencing array for dilated cardiomyopathy , 2010, Genetics in Medicine.

[35]  Susan Y. Chen,et al.  Myosin ATP turnover rate is a mechanism involved in thermogenesis in resting skeletal muscle fibers , 2009, Proceedings of the National Academy of Sciences.

[36]  Heidi L Rehm,et al.  Shared genetic causes of cardiac hypertrophy in children and adults. , 2008, The New England journal of medicine.

[37]  A. E. Rossi,et al.  RyR1 S-Nitrosylation Underlies Environmental Heat Stroke and Sudden Death in Y522S RyR1 Knockin Mice , 2008, Cell.

[38]  S. Hamilton,et al.  Identification of Cysteines Involved in S-Nitrosylation, S-Glutathionylation, and Oxidation to Disulfides in Ryanodine Receptor Type 1* , 2006, Journal of Biological Chemistry.

[39]  Anselm H. C. Horn,et al.  AMBER force-field parameters for phosphorylated amino acids in different protonation states: phosphoserine, phosphothreonine, phosphotyrosine, and phosphohistidine , 2006, Journal of molecular modeling.

[40]  M. Komajda,et al.  Mutation screening in dilated cardiomyopathy: prominent role of the beta myosin heavy chain gene. , 2005, European heart journal.

[41]  F. Mastaglia,et al.  Mutations in the slow skeletal muscle fiber myosin heavy chain gene (MYH7) cause laing early-onset distal myopathy (MPD1). , 2004, American journal of human genetics.

[42]  András Fiser,et al.  ModLoop: automated modeling of loops in protein structures , 2003, Bioinform..

[43]  P. Allen,et al.  FKBP12 Binding to RyR1 Modulates Excitation-Contraction Coupling in Mouse Skeletal Myotubes* , 2003, Journal of Biological Chemistry.

[44]  E. Homsher,et al.  Regulation of contraction in striated muscle. , 2000, Physiological reviews.

[45]  J. Seidman,et al.  Familial hypertrophic cardiomyopathy and atrial fibrillation caused by Arg663His beta-cardiac myosin heavy chain mutation. , 1999, The American journal of cardiology.

[46]  K. Nair,et al.  Effects of aging on in vivo synthesis of skeletal muscle myosin heavy-chain and sarcoplasmic protein in humans. , 1997, American journal of physiology. Endocrinology and metabolism.

[47]  M. Rennie,et al.  The measurement of tissue protein turnover. , 1996, Bailliere's clinical endocrinology and metabolism.

[48]  R A Milligan,et al.  Structure of the actin-myosin complex and its implications for muscle contraction. , 1993, Science.

[49]  W. Kabsch,et al.  Dictionary of protein secondary structure: Pattern recognition of hydrogen‐bonded and geometrical features , 1983, Biopolymers.

[50]  J. Sellers,et al.  Utility of genetic screening in hypertrophic cardiomyopathy: prevalence and significance of novel and double (homozygous and heterozygous) beta-myosin mutations. , 2003, Genetic testing.